

# Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis, December 2012

<https://marketpublishers.com/r/TEBDD5C0D5CEN.html>

Date: December 2012

Pages: 0

Price: US\$ 1,980.00 (Single User License)

ID: TEBDD5C0D5CEN

## Abstracts

The global cardiovascular drugs industry experienced average growth over the last five years and is expected to reach approximately US \$174.8 billion in 2017, growing with a CAGR of 2.9% over the next five years. Top companies are making strategic acquisitions both to expand their global footprints and to take advantage of established business and expertise gained from acquired companies.

Lucintel, a leading global management consulting and market research firm, has conducted a competitive analysis of the leading global cardiovascular drugs companies and presents its findings in “Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis.” The report provides detailed insights into the performance of the top five companies across the world. The analysis highlights the companies that are performing the best among the peer group, and in which areas, and therefore clarifies leading performance standards and the strengths and weaknesses of companies covered.

The global cardiovascular drugs industry is consolidated with all classes of drugs used for the treatment of cardiovascular diseases such as hypertension, high cholesterol, heart failure, acute stroke, abnormal rhythms of the heart, chest pain, and other cardiac disorders. The industry is dominated by the North America region. In this study, Lucintel thoroughly profiles the following five companies with detailed competitive assessments:

AstraZeneca

Bristol-Myers Squibb

Novartis

Pfizer

Sanofi

As indicated in the study, the thrombotic drugs segment is currently small, but holds great growth potential in the future. The launch and development of new products, incorporated with innovative technologies, will drive the growth as manufacturers look for ways to differentiate themselves from their competitors.

This study is intended to provide industry leaders with a competitive benchmarking of the world's top five cardiovascular drugs companies. The study provides up-to-date information on the market share, profit margins, capabilities, and strategies of the leaders. It is designed to provide executives with strategically significant competitor information, data analysis and insight, critical to the development and implementation of an effective marketing and sales plan.

This report will save hundreds of hours of your own personal research time and will significantly benefit you in expanding your business opportunities in global cardiovascular drug companies industry. In today's chaotic economy, you need every advantage that you can find to keep ahead in your business

## Contents

- 1. EXECUTIVE SUMMARY**
- 2. MARKET DEFINITION AND SCOPE**
- 3. MARKET OPPORTUNITY**
- 4. COMPETITIVE BENCHMARKING (FINANCIAL AND MARKET)**

### **Company Profile on Following Parameters**

- Company Overview**
- Benchmarking (Financial & Market)**
- SWOT Analysis**
- Product Positioning**
- Marketing Strategy and Tactics**
- Corporate Strategy**

- 5. COMPANY PROFILE ON ASTRAZENECA**
- 6. COMPANY PROFILE ON BRISTOL-MYERS SQUIBB**
- 7. COMPANY PROFILE ON NOVARTIS**
- 8. COMPANY PROFILE ON PFIZER**
- 9. COMPANY PROFILE ON SANOFI**

## List Of Figures

### LIST OF FIGURES AND CHARTS

#### CHAPTER 3. Market Opportunity

Figure 3.1: Supply chain for cardiovascular drug market

Figure 3.2: Global cardiovascular drug industry annual trend 2006-2011 (US \$B)

Figure 3.3: Global cardiovascular drug industry regional trend 2006-2011 (US \$B)

Figure 3.4: Global cardiovascular drug industry regional trend 2006-2011 (%)

Figure 3.5: Global cardiovascular drug industry segment trend 2006-2011 (US \$B)

Figure 3.6: Global cardiovascular drug industry segment trend 2006-2011 (%)

Figure 3.7: Global cardiovascular drug industry opportunity by region

Figure 3.8: Global cardiovascular drug industry opportunity by segment

#### CHAPTER 4. Competitive Benchmarking (Financial and Market)

Figure 4.1: Top five cardiovascular drug companies – financial benchmarking

Figure 4.2: Global top five cardiovascular drug companies gross profit and net profit analysis – 2011

Figure 4.3: Financial analysis – growth leadership quadrant (2011)

Figure 4.4: Market share of top players 2006

Figure 4.5: Market share of top players 2011

Figure 4.6: 2006 Market share analysis

Figure 4.7: 2011 Market share analysis

Figure 4.8: Global market share analysis 2011

Figure 4.9: Global market fragmentation 2011

Figure 4.10: Market value North America: (US \$B)

Figure 4.11: Market value Europe: (US \$B)

Figure 4.12: Market value Asia Pacific: (US \$B)

Figure 4.13: Market value Row: (US \$B)

Figure 4.14: Regional revenue evaluation 2011(US \$M)

Figure 4.15: Regional revenue evaluation 2011(%)

Figure 4.16: North American revenue trend for top players 2007-2011 (US \$B)

Figure 4.17: Europe revenue trend for top players 2007-2011 (US \$B)

Figure 4.18: Asia Pacific revenue trend for top players 2007-2011 (US \$B)

Figure 4.19: Row revenue trend for top players 2007-2011 (US \$B)

Figure 4.20: Lucintel triad - top five major players

#### CHAPTER 5. Company Profile of AstraZeneca

Figure 5.1: AstraZeneca's revenue by business structure 2011

Figure 5.2: Lucintel Triad – AstraZeneca

Figure 5.3: Financial benchmarking AstraZeneca against top three and top five industry

players' average

Figure 5.4: Financial benchmarking of AstraZeneca against Top Five best

Figure 5.5: Global industry revenue trend Vs AstraZeneca (2007-2011) in US \$B

Figure 5.6: Global market share trend for AstraZeneca (2007-2011) in (%)

Figure 5.7: North American industry revenue trend Vs AstraZeneca 2007-2011 in (US \$B)

Figure 5.8: European industry revenue trend Vs AstraZeneca 2007-2011 in (US \$B)

Figure 5.9: APAC industry revenue trend Vs AstraZeneca 2007-2011 in (US \$B)

Figure 5.10: ROW industry revenue trend Vs AstraZeneca 2007-2011 in (US \$B)

Figure 5.11: North American market share trend Vs AstraZeneca 2007-2011 in (%)

Figure 5.12: European market share trend Vs AstraZeneca 2007-2011 in (%)

Figure 5.13: APAC market share trend Vs AstraZeneca 2007-2011 in (%)

Figure 5.14: ROW market share trend Vs AstraZeneca 2007-2011 in (%)

Figure 5.15: AstraZeneca trend in R&D expenses 2007-2011 in US \$B

Figure 5.16: AstraZeneca trend in R&D expenses Percentage of total revenue

Figure 5.17: Comparison of AstraZeneca SE R&D expenditure vs. top three & top five players average 2011

Figure 5.18: AstraZeneca productivity 2007-2011 (US \$M)

Figure 5.19: AstraZeneca capital investment value 2007-2011 (US \$M)

Figure 5.20: Strategic execution

## CHAPTER 6. Company Profile of Bristol-Myers Squibb

Figure 6.1: Bristol-Myers Squibb revenue by business structure 2011

Figure 6.2: Lucintel triad - Bristol-Myers Squibb

Figure 6.3: Financial benchmarking of Bristol-Myers Squibb against top three and top five industry players' average

Figure 6.4: Financial benchmarking of Bristol-Myers Squibb against Top five best

Figure 6.5: Global industry revenue trend Vs Bristol-Myers Squibb (2007-2011) in (US \$B)

Figure 6.6: Global market share trend for Bristol-Myers Squibb (2007-2011) in (%)

Figure 6.7: North American industry revenue trend Vs. Bristol-Myers Squibb 2007-2011 in (US \$B)

Figure 6.8: European industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US \$B)

Figure 6.9: APAC industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US \$B)

Figure 6.10: ROW industry revenue trend Vs Bristol-Myers Squibb 2007-2011 in (US \$B)

Figure 6.11: North American market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)

Figure 6.12: European market share trend Vs Bristol-Myers Squibb 2007-2011 in (%)

Figure 6.13: APAC market share trend Vs DuPont 2007-2011 in (%)

Figure 6.14: ROW market share trend Vs DuPont 2007-2011 in (%)

Figure 6.15: Bristol-Myers Squibb trend in R&D expenses 2007-2011 in US \$B

Figure 6.16: Bristol-Myers Squibb trend in R&D expenses Percentage of total revenue

Figure 6.17: Comparison of Bristol-Myers Squibb SE R&D expenditure Vs top three & top five players average 2011

Figure 6.18: Bristol-Myers Squibb productivity: 2007-2011 in (US \$M)

Figure 6.19: Bristol-Myers Squibb capital investment value: 2007-2011 in (US \$M)

Figure 6.20: Strategic execution

## CHAPTER 7. Company Profile of Novartis

Figure 7.1: Novartis revenue by business structure 2011

Figure 7.2: Lucintel triad – Novartis

Figure 7.3: Financial benchmarking of Novartis against top three and top five industry players' average

Figure 7.4: Financial benchmarking of Novartis against Top five best

Figure 7.5: Global industry revenue trend Vs Novartis (2007-2011) in (US \$B)

Figure 7.6: Global market share trend for Novartis (2007-2011) in (%)

Figure 7.7: North American industry revenue trend Vs Novartis (2007-2011) in (US \$B)

Figure 7.8: European industry revenue trend Vs Novartis I (2007-2011) in (US \$B)

Figure 7.9: APAC industry revenue trend Vs Novartis (2007-2011) in (US \$B)

Figure 7.10: ROW industry revenue trend Vs Novartis (2007-2011) in (US \$B)

Figure 7.11: North American market share trend Vs Novartis (2007-2011) in (%)

Figure 7.12: European market share trend Vs Novartis I (2007-2011) in (%)

Figure 7.13: APAC market share trend Vs Novartis (2007-2011) in (%)

Figure 7.14: ROW market share trend Vs Novartis (2007-2011) in (%)

Figure 7.15: Novartis trend in R&D expenses 2007-2011 in US \$B

Figure 7.16: Novartis trend in R&D expenses Percentage of total revenue

Figure 7.17: Comparison of Novartis R&D expenditure vs top three & top five players average 2011

Figure 7.18: Novartis productivity: 2007-2011 in (US \$M)

Figure 7.19: Novartis capital investment value: 2007-2011 in (US \$M)

Figure 7.20: Strategic execution

## CHAPTER 8. Company Profile of Pfizer

Figure 8.1: Pfizer revenue by business structure 2011

Figure 8.2: Lucintel triad – Pfizer

Figure 8.3: Financial benchmarking of Pfizer against top three and top five industry players' average

Figure 8.4: Financial benchmarking of Pfizer against Top five best

Figure 8.5: Global industry revenue trend Vs Pfizer (2007-2011) in (US \$B)

- Figure 8.6: Global market share trend for Pfizer (2007-2011) in (%)
- Figure 8.7: North American industry revenue trend Vs Pfizer (2007-2011) in (US \$B)
- Figure 8.8: European industry revenue trend Vs Pfizer (2007-2011) in (US \$B)
- Figure 8.9: APAC industry revenue trend Vs Pfizer (2007-2011) in (US \$B)
- Figure 8.10: ROW industry revenue trend Vs Pfizer (2007-2011) in (US \$B)
- Figure 8.11: North American market share trend Vs Pfizer (2007-2011) in (%)
- Figure 8.12: European market share trend Vs Pfizer (2007-2011) in (%)
- Figure 8.13: APAC market share trend Vs Pfizer (2007-2011) in (%)
- Figure 8.14: ROW market share trend Vs Pfizer (2007-2011) in (%)
- Figure 8.15: Pfizer trend in R&D expenses 2007-2011 in US \$B
- Figure 8.16: Pfizer trend in R&D expenses Percentage of total revenue
- Figure 8.17: Comparison of Pfizer R&D expenditure vs top three & top five players average 2011
- Figure 8.18: Pfizer productivity: 2007-2011 in (US \$M)
- Figure 8.19: Pfizer capital investment value: 2007-2011 in (US \$M)
- Figure 8.20: Strategic execution
- CHAPTER 9. Company Profile of Sanofi
- Figure 9.1: Sanofi revenue by business structure 2011
- Figure 9.2: Lucintel triad – Sanofi
- Figure 9.3: Financial benchmarking of Sanofi against top three and top five industry players' average
- Figure 9.4: Financial benchmarking of Sanofi against Top five best
- Figure 9.5: Global industry revenue trend Vs Sanofi (2007-2011) in (US \$B)
- Figure 9.6: Global market share trend for Sanofi (2007-2011) in (%)
- Figure 9.7: North American industry revenue trend Vs Sanofi (2007-2011) in (US \$B)
- Figure 9.8: European industry revenue trend Vs Sanofi (2007-2011) in (US \$B)
- Figure 9.9: APAC industry revenue trend Vs Sanofi (2007-2011) in (US \$B)
- Figure 9.10: ROW industry revenue trend Vs Sanofi (2007-2011) in (US \$B)
- Figure 9.11: North American market share trend Vs Sanofi (2007-2011) in (%)
- Figure 9.12: European market share trend Vs Sanofi (2007-2011) in (%)
- Figure 9.13: APAC market share trend Vs Sanofi (2007-2011) in (%)
- Figure 9.14: ROW market share trend Vs Sanofi (2007-2011) in (%)
- Figure 9.15: Sanofi trend in R&D expenses 2007-2011 in US \$B
- Figure 9.16: Sanofi trend in R&D expenses Percentage of total revenue
- Figure 9.17: Comparison of Sanofi R&D expenditure vs top three & top five players average 2011
- Figure 9.18: Sanofi productivity: 2007-2011 in (US \$M)
- Figure 9.19: Sanofi capital investment value: 2007-2011 in (US \$M)
- Figure 9.20: Strategic execution





## List Of Tables

### LIST OF TABLES

#### CHAPTER 3. Market Opportunity

Table 3.1: Industry parameters of global cardiovascular drug industry

Table 3.2: Relative market attractiveness by region

Table 3.3: Regional revenue growth rate

Table 3.4: Segment revenue growth rate

#### CHAPTER 4. Competitive Benchmarking (Financial and Market)

Table 4.1: Financial benchmarking of top five global cardiovascular drug companies

Table 4.2: Key financial parameters for top five cardiovascular drug companies

Table 4.3: Regional revenue (US \$M)

Table 4.4: Regional revenue (%)

Table 4.5: Competitors based on markets served

Table 4.6: Lucintel triad - Top five major players

#### CHAPTER 5. Company Profile of AstraZeneca

Table 5.1: Market served: AstraZeneca

Table 5.2: Lucintel triad – AstraZeneca

Table 5.3: Financial Benchmarking of AstraZeneca against best and against Top three and Top five industry players' average

Table 5.4: Strategic execution – product positioning by segment

Table 5.5: Strategic execution – perceived customer value / quality

Table 5.6: Strategic execution – promotion / communications

Table 5.7: Strategic execution – product distribution by region

#### CHAPTER 6. Company Profile of Bristol-Myers Squibb

Table 6.1: Market served – Bristol-Myers Squibb

Table 6.2: Lucintel triad – Bristol-Myers Squibb

Table 6.3: Financial benchmarking of Bristol-Myers Squibb against best and against Top three and Top five industry players' average

Table 6.4: Strategic execution – product positioning by segment

Table 6.5: Strategic execution – perceived customer value / quality

Table 6.6: Strategic execution – promotion / communications

Table 6.7: Strategic execution – product distribution by region

#### CHAPTER 7. Company Profile of Novartis

Table 7.1: Market served – Novartis

Table 7.2: Lucintel triad – Novartis

Table 7.3: Financial benchmarking of Novartis against best and against Top three and Top five industry players' average

Table 7.4: Strategic execution – product positioning by segment

Table 7.5: Strategic execution – perceived customer value / quality

Table 7.6: Strategic execution – promotion / communications

Table 7.7: Strategic execution – product distribution by region

#### CHAPTER 8. Company Profile of Pfizer

Table 8.1: Market served – Pfizer

Table 8.2: Lucintel triad – Pfizer

Table 8.3: Financial Benchmarking of Pfizer against best and against Top three and top five industry players' average

Table 8.4: Strategic execution – product positioning by segment

Table 8.5: Strategic execution – perceived customer value / quality

Table 8.6: Strategic execution – promotion / communications

Table 8.7: Strategic execution – product distribution by region

#### CHAPTER 9. Company Profile of Sanofi

Table 9.1: Markets Served – Sanofi

Table 9.2: Lucintel triad – Sanofi

Table 9.3: Financial Benchmarking of Sanofi against best and against Top three and top five industry players' average

Table 9.4: Strategic execution – product positioning by segment

Table 9.5: Strategic execution – perceived customer value / quality

Table 9.6: Strategic execution – promotion / communications

Table 9.7: Strategic execution – product distribution by region

## I would like to order

Product name: Top Five Global Cardiovascular Drug Companies: Performance, Strategies, and Competitive Analysis, December 2012

Product link: <https://marketpublishers.com/r/TEBDD5C0D5CEN.html>

Price: US\$ 1,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TEBDD5C0D5CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

